Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 7.2% – Should You Sell?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) dropped 7.2% during mid-day trading on Tuesday . The company traded as low as $10.65 and last traded at $10.4380. Approximately 284,627 shares changed hands during trading, a decline of 63% from the average daily volume of 759,141 shares. The stock had previously closed at $11.25.

Analyst Ratings Changes

KYTX has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $28.67.

Kyverna Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.11, a current ratio of 7.75 and a quick ratio of 7.75. The firm has a market capitalization of $614.92 million, a P/E ratio of -2.78 and a beta of 2.62. The firm’s 50 day simple moving average is $8.49 and its two-hundred day simple moving average is $8.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.80) earnings per share for the quarter, hitting the consensus estimate of ($0.80). As a group, analysts predict that Kyverna Therapeutics, Inc. will post -3.24 earnings per share for the current year.

Institutional Trading of Kyverna Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Grey Ledge Advisors LLC bought a new stake in Kyverna Therapeutics in the first quarter worth $86,000. Banque Cantonale Vaudoise bought a new stake in Kyverna Therapeutics in the first quarter worth $263,000. Empowered Funds LLC bought a new stake in Kyverna Therapeutics in the fourth quarter worth $169,000. Quadrature Capital Ltd bought a new stake in Kyverna Therapeutics in the fourth quarter worth $539,000. Finally, Millennium Management LLC lifted its stake in Kyverna Therapeutics by 7.6% in the fourth quarter. Millennium Management LLC now owns 593,369 shares of the company’s stock worth $5,578,000 after purchasing an additional 41,734 shares during the last quarter. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.